Harmicine



Compound IDCDAMM01869
Common nameHarmicine
IUPAC name2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole
Molecular formulaC14H16N2

Experimental data

Retention time0.49
Adduct[2M+K]+
Actual mz463.221
Theoretical mz463.225
Error9.41
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.3418

Identifiers and class information

Inchi keyLXJWBHIVLXMHDZ-UGPWUYPHNA-N
SmilesC=1C=CC2=C(C1)NC3=C2CCN4CCCC34
SuperclassOrganoheterocyclic compounds
ClassIndoles and derivatives

Plant source

  • Curcuma longa L.

    • Pharmacokinetic properties

    Number of descriptor values(#stars)0
    Number of non-conjugated amine groups (#amine)1
    Number of amidine and guanidine groups (#amidine)0
    Number of carboxylic acid groups (#acid)0
    Number of non-conjugated amide groups (#amide)0
    Number of rotatable bonds (#rotor)0
    Number of reactive functional groups (#rtvFG)0
    Predicted central nervous system activity (CNS)2
    Molecular weight (mol_MW)212.294
    Computed dipole moment(dipole)3.312
    Total solvent accessible surface area (SASA)453.553
    Hydrophobic component of SASA (FOSA)249.733
    Hydrophilic component of SASA (FISA)22.228
    Pie component of the SASA (PISA)181.592
    Weakly polar component of the SASA (WPSA)0
    Total solvent accesible volume (volume)760.192
    Number of hydrogen bond donors (donorHB)1
    Number of hydrogen bond acceptors (accptHB)2
    Free energy of solvation of dipole (dip^2/V)0.0144262
    Index of cohesive interaction in solids (ACxDN^.5/SA)0.0044096
    Globularity descriptor (glob)0.88815
    Predicted polarizability in cubic angstroms (QPpolrz)26.003
    Predicted hexadecane/gas partition coefficient (QPlogPC16)7.003
    Predicted octanol/gas partition coefficient (QPlogPoct)10.617
    Predicted water/gas partition coefficient (QPlogPw)5.632
    Predicted octanol/water partition coefficient (QPlogPo/w)2.708
    Predicted aqueous solubility (QPlogS)-2.585
    Conformation-independent predicted aqueous solubility (CIQPlogS)-2.201
    Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.934
    Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1520.59
    Predicted brain/blood partition coefficient (QPlogBB)0.774
    Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)860.923
    Predicted skin permeability, log Kp (QPlogKp)-3.352
    PM3 calculated ionization potential (IP(ev))8.022
    PM3 calculated electron affinity (EA(eV))-0.17
    Number of likely metabolic reactions (#metab)2
    Prediction of binding to human serum albumin (QPlogKhsa)0.296
    Predicted qualitative human oral absorption (HumanOralAbsorption)3
    Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)100
    Solvent-accessible surface area of fluorine atoms (SAFluorine)0
    Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
    Van der Waals surface area (PSA)19.066
    Number of nitrogen and oxygen atoms (#NandO)2
    Number of violations of Lipinski’s rule of five (RuleOfFive)0
    Number of violations of Jorgensen’s rule of three (RuleOfThree)0

    Compound-target network

    Cytoscape Graph

    Protein targets associated with phytocompound

    Uniprot ID Gene name Target name TTD_ID Prediction source
    Q99720SIGMAR1Sigma opioid receptorT46360SwissTargetPrediction and SEA
    P14416DRD2Dopamine D2 receptorT67162SwissTargetPrediction
    P23280CA6Carbonic anhydrase VIT06569SEA
    P22748CA4Carbonic anhydrase IVT53378SEA
    P28223HTR2ASerotonin 2a (5-HT2a) receptorT32060SwissTargetPrediction
    P31645SLC6A4Serotonin transporter (by homology)T27812SwissTargetPrediction
    P08908HTR1ASerotonin 1a (5-HT1a) receptorT78709SwissTargetPrediction
    P50406HTR6Serotonin 6 (5-HT6) receptorT16691SwissTargetPrediction
    Q01959SLC6A3Dopamine transporterT55959SwissTargetPrediction
    P35462DRD3Dopamine D3 receptorT02551SwissTargetPrediction
    P21728DRD1Dopamine D1 receptorT22118SEA
    P21918DRD5Dopamine D5 receptorT46828SEA
    P18825ADRA2CAdrenergic receptor alpha-2T01777SEA
    P35372OPRM1Mu opioid receptorT47768SwissTargetPrediction and SEA
    P41145OPRK1Kappa Opioid receptorT60693SEA
    P52732KIF11Kinesin-like protein 1T28484SEA
    P06276BCHEButyrylcholinesteraseT99799SwissTargetPrediction
    P41143OPRD1Delta opioid receptorT58992SEA
    P18089ADRA2BAlpha-2b adrenergic receptorT41580SEA
    P32745SSTR3Somatostatin receptor 3T13644SEA
    O76074PDE5APhosphodiesterase 5AT07663SEA
    Q14330GPR18N-arachidonyl glycine receptorT72267SEA
    Q9HCR9PDE11APhosphodiesterase 11AT99802SEA
    P49862KLK7Kallikrein-7T79155SEA

    Target associated diseases

    TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
    T46360DI0105Cough[ICD-11: MD12]Q99720SIGMAR1
    T67162DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P14416DRD2
    T67162DI0025Alzheimer disease[ICD-11: 8A20]P14416DRD2
    T67162DI0037Asthma[ICD-11: CA23]P14416DRD2
    T67162DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P14416DRD2
    T67162DI0051Bipolar disorder[ICD-11: 6A60]P14416DRD2
    T67162DI0063Breathing abnormality[ICD-11: MD11]P14416DRD2
    T67162DI0070Cardiovascular disease[ICD-11: BA00-BE2Z]P14416DRD2
    T67162DI0073Cerebral ischaemia[ICD-11: 8B1Z]P14416DRD2
    T67162DI0117Depression[ICD-11: 6A70-6A7Z]P14416DRD2
    T67162DI0124Digestive system disease[ICD-11: DE2Z]P14416DRD2
    T67162DI0137Essential hypertension[ICD-11: BA00]P14416DRD2
    T67162DI0142Faecal incontinence[ICD-11: ME07]P14416DRD2
    T67162DI0156Gangrene[ICD-11: MC85]P14416DRD2
    T67162DI0166Glaucoma[ICD-11: 9C61]P14416DRD2
    T67162DI0175Heart failure[ICD-11: BD10-BD1Z]P14416DRD2
    T67162DI0185Hyperaemia[ICD-11: 9A61-9B7Y]P14416DRD2
    T67162DI0190Hypertension[ICD-11: BA00-BA04]P14416DRD2
    T67162DI0196Hypotension[ICD-11: BA20-BA21]P14416DRD2
    T67162DI0205Inborn porphyrin/heme metabolism error[ICD-11: 5C58]P14416DRD2
    T67162DI0214Insomnia[ICD-11: 7A00-7A0Z]P14416DRD2
    T67162DI0222Itching[ICD-11: 1F28-1G07]P14416DRD2
    T67162DI0264Migraine[ICD-11: 8A80]P14416DRD2
    T67162DI0293Nausea/vomiting[ICD-11: MD90]P14416DRD2
    T67162DI0324Pain[ICD-11: MG30-MG3Z]P14416DRD2
    T67162DI0331Parkinsonism[ICD-11: 8A00]P14416DRD2
    T67162DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P14416DRD2
    T67162DI0340Postpartum haemorrhage[ICD-11: JA43]P14416DRD2
    T67162DI0354Psychotic disorder[ICD-11: 6A20-6A25]P14416DRD2
    T67162DI0356Pulmonary hypertension[ICD-11: BB01]P14416DRD2
    T67162DI0370Schizophrenia[ICD-11: 6A20]P14416DRD2
    T67162DI0396Substance abuse[ICD-11: 6C40]P14416DRD2
    T67162DI0408Thyrotoxicosis[ICD-11: 5A02]P14416DRD2
    T67162DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P14416DRD2
    T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
    T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
    T53378DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P22748CA4
    T53378DI0166Glaucoma[ICD-11: 9C61]P22748CA4
    T53378DI0372Seborrhoeic dermatitis[ICD-11: EA81]P22748CA4
    T32060DI0009Acute diabete complication[ICD-11: 5A2Y]P28223HTR2A
    T32060DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P28223HTR2A
    T32060DI0073Cerebral ischaemia[ICD-11: 8B1Z]P28223HTR2A
    T32060DI0270Mood disorder[ICD-11: 6A60-6E23]P28223HTR2A
    T32060DI0331Parkinsonism[ICD-11: 8A00]P28223HTR2A
    T32060DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28223HTR2A
    T32060DI0370Schizophrenia[ICD-11: 6A20]P28223HTR2A
    T27812DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P31645SLC6A4
    T27812DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P31645SLC6A4
    T27812DI0087Chronic pain[ICD-11: MG30]P31645SLC6A4
    T27812DI0096concerning food/fluid intake symptom[ICD-11: MG43]P31645SLC6A4
    T27812DI0101Corneal disease[ICD-11: 9A76-9A78]P31645SLC6A4
    T27812DI0105Cough[ICD-11: MD12]P31645SLC6A4
    T27812DI0117Depression[ICD-11: 6A70-6A7Z]P31645SLC6A4
    T27812DI0264Migraine[ICD-11: 8A80]P31645SLC6A4
    T27812DI0301Nicotine use disorder[ICD-11: 6C4A]P31645SLC6A4
    T27812DI0308Obesity[ICD-11: 5B80-5B81]P31645SLC6A4
    T27812DI0324Pain[ICD-11: MG30-MG3Z]P31645SLC6A4
    T78709DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P08908HTR1A
    T78709DI0117Depression[ICD-11: 6A70-6A7Z]P08908HTR1A
    T78709DI0190Hypertension[ICD-11: BA00-BA04]P08908HTR1A
    T78709DI0264Migraine[ICD-11: 8A80]P08908HTR1A
    T78709DI0270Mood disorder[ICD-11: 6A60-6E23]P08908HTR1A
    T16691DI0025Alzheimer disease[ICD-11: 8A20]P50406HTR6
    T16691DI0370Schizophrenia[ICD-11: 6A20]P50406HTR6
    T55959DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]Q01959SLC6A3
    T55959DI0051Bipolar disorder[ICD-11: 6A60]Q01959SLC6A3
    T55959DI0101Corneal disease[ICD-11: 9A76-9A78]Q01959SLC6A3
    T55959DI0290Narcolepsy[ICD-11: 7A20]Q01959SLC6A3
    T55959DI0308Obesity[ICD-11: 5B80-5B81]Q01959SLC6A3
    T55959DI0331Parkinsonism[ICD-11: 8A00]Q01959SLC6A3
    T02551DI0051Bipolar disorder[ICD-11: 6A60]P35462DRD3
    T02551DI0331Parkinsonism[ICD-11: 8A00]P35462DRD3
    T22118DI0003Abortion[ICD-11: JA00]P21728DRD1
    T22118DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P21728DRD1
    T22118DI0190Hypertension[ICD-11: BA00-BA04]P21728DRD1
    T22118DI0331Parkinsonism[ICD-11: 8A00]P21728DRD1
    T46828DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P21918DRD5
    T01777DI0166Glaucoma[ICD-11: 9C61]P18825ADRA2C
    T01777DI0190Hypertension[ICD-11: BA00-BA04]P18825ADRA2C
    T01777DI0196Hypotension[ICD-11: BA20-BA21]P18825ADRA2C
    T01777DI0308Obesity[ICD-11: 5B80-5B81]P18825ADRA2C
    T01777DI0310Ocular disease[ICD-11: N.A.]P18825ADRA2C
    T01777DI0396Substance abuse[ICD-11: 6C40]P18825ADRA2C
    T47768DI0013Acute pain[ICD-11: MG31]P35372OPRM1
    T47768DI0059Bowel habit change[ICD-11: ME05]P35372OPRM1
    T47768DI0087Chronic pain[ICD-11: MG30]P35372OPRM1
    T47768DI0101Corneal disease[ICD-11: 9A76-9A78]P35372OPRM1
    T47768DI0105Cough[ICD-11: MD12]P35372OPRM1
    T47768DI0117Depression[ICD-11: 6A70-6A7Z]P35372OPRM1
    T47768DI0124Digestive system disease[ICD-11: DE2Z]P35372OPRM1
    T47768DI0218Irritable bowel syndrome[ICD-11: DD91]P35372OPRM1
    T47768DI0228Large intestine motility disorder[ICD-11: DB32]P35372OPRM1
    T47768DI0317Opioid use disorder[ICD-11: 6C43]P35372OPRM1
    T47768DI0324Pain[ICD-11: MG30-MG3Z]P35372OPRM1
    T47768DI0349Pruritus[ICD-11: EC90]P35372OPRM1
    T47768DI0374Sensation disturbance[ICD-11: MB40]P35372OPRM1
    T60693DI0304Non-specific cutaneous vascular symptom[ICD-11: ME64]P41145OPRK1
    T60693DI0324Pain[ICD-11: MG30-MG3Z]P41145OPRK1
    T60693DI0349Pruritus[ICD-11: EC90]P41145OPRK1
    T28484DI0012Acute myeloid leukaemia[ICD-11: 2A60]P52732KIF11
    T28484DI0172Head and neck cancer[ICD-11: 2D42]P52732KIF11
    T28484DI0241Lymphoma[ICD-11: 2A80-2A86]P52732KIF11
    T28484DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P52732KIF11
    T28484DI0274Multiple myeloma[ICD-11: 2A83]P52732KIF11
    T28484DI0321Ovarian cancer[ICD-11: 2C73]P52732KIF11
    T28484DI0361Renal cell carcinoma[ICD-11: 2C90]P52732KIF11
    T28484DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P52732KIF11
    T99799DI0324Pain[ICD-11: MG30-MG3Z]P06276BCHE
    T99799DI0411Tonus and reflex abnormality[ICD-11: MB47]P06276BCHE
    T58992DI0059Bowel habit change[ICD-11: ME05]P41143OPRD1
    T58992DI0218Irritable bowel syndrome[ICD-11: DD91]P41143OPRD1
    T58992DI0324Pain[ICD-11: MG30-MG3Z]P41143OPRD1
    T41580DI0396Substance abuse[ICD-11: 6C40]P18089ADRA2B
    T13644DI0108Cushing syndrome[ICD-11: 5A70]P32745SSTR3
    T07663DI0190Hypertension[ICD-11: BA00-BA04]O76074PDE5A
    T07663DI0213Innate/adaptive immunodeficiency[ICD-11: 4A00]O76074PDE5A
    T07663DI0378Sexual dysfunction[ICD-11: HA00-HA01]O76074PDE5A
    T07663DI0411Tonus and reflex abnormality[ICD-11: MB47]O76074PDE5A

    Copyright © 2025